Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:appointed_by |
inhalation
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:brand |
Advair Diskus
Advair HFA |
| gptkbp:class |
gptkb:physicist
long-acting beta agonist |
| gptkbp:clinical_trial |
Phase IV
Phase III preventive treatment maintenance treatment long-term control |
| gptkbp:contains |
fluticasone
salmeterol |
| gptkbp:contraindication |
hypersensitivity to components
|
| gptkbp:dosage_form |
powder
aerosol |
| gptkbp:formulation |
dry powder inhaler
metered-dose inhaler |
| https://www.w3.org/2000/01/rdf-schema#label |
Advair
|
| gptkbp:ingredients |
fluticasone propionate
salmeterol xinafoate |
| gptkbp:interacts_with |
MAO inhibitors
diuretics beta-blockers |
| gptkbp:invention |
gptkb:2010
|
| gptkbp:is_available_on |
HFA inhaler
diskus |
| gptkbp:is_used_for |
gptkb:asthma
chronic obstructive pulmonary disease |
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:marketed_as |
gptkb:UK
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver highly protein-bound |
| gptkbp:population |
gptkb:Person
adults |
| gptkbp:previous_name |
fluticasone/salmeterol
|
| gptkbp:provides_information_on |
GINA guidelines
NHLBI guidelines |
| gptkbp:research |
Impact on quality of life
Comparative effectiveness with other inhalers Dosing frequency and adherence Efficacy in asthma control Long-term safety in COPD |
| gptkbp:safety_features |
monitor for adrenal insufficiency
not recommended for children under 4 risk of pneumonia in COPD patients |
| gptkbp:scholarships |
consult doctor if symptoms worsen
not to exceed prescribed dose not for immediate relief of acute symptoms |
| gptkbp:side_effect |
headache
nausea cough hoarseness thrush |
| gptkbp:storage |
room temperature
protected from moisture |